RxDoctor Payments Data

Heather Thompson, APRN

Primary Care · Waverly, TNNPI 1477124881

Payments from drug & device makers

$566in general payments, 2019–2025

Across 30 payments — averaging $18.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$356
  • Axsome Therapeutics, Inc.$58
  • Galderma Laboratories, L.p.$54
  • AstraZeneca$36
  • Pfizer$19
  • Lilly USA, LLC$17
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$566100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$566 in reported general payments places this provider in the 50th percentile of 189 primary care providers in Tennessee.

See all primary care providers in Tennessee

Medicare billing

Part B allowed, 2024
$40,843
Medicare patients
121
Services billed
1,415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib11$82,132
OzempicSemaglutide61$60,298
MounjaroTirzepatide20$25,024
EliquisApixaban35$23,302
VraylarCariprazine Hcl15$22,301
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$16,410
JardianceEmpagliflozin22$15,723
Nurtec OdtRimegepant Sulfate11$10,670
TrintellixVortioxetine Hydrobromide15$7,235
Dexlansoprazole DrDexlansoprazole12$3,092
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$1,903
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen66$1,877
Pregabalin47$1,642
Gabapentin112$1,447
Duloxetine Hcl68$1,288

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Vraylar$356$104,43426 claims
Novo NordiskOzempic$15$60,29861 claims
PfizerEliquis, Nurtec Odt$19$33,97246 claims
Lilly USA, LLCMounjaro$17$25,02420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 189 primary care providers in Tennessee.

Other primary care in Waverly

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →